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Background: Inappropriate polypharmacy may negatively impact quality of life of residents 
in aged care facilities, but it remains unclear which medications may influence this reduced 
quality of life.  
Objective: The objective was to examine whether the Drug Burden Index (DBI) and 
potentially inappropriate medications (PIMs), were associated with quality of life in older 
adults living in residential care with a high prevalence of cognitive impairment and dementia.  
Methods: Cross-sectional analyses of 541individuals recruited from 17 residential aged care 
facilities in Australia in the Investigating Services Provided in the Residential Environment 
for Dementia (INSPIRED) study. Quality of life was measured using the EQ-5D-5L (a 
measure of generic quality of life) and the DEMQOL (a measure developed for use in 
dementia) completed by the participant or a proxy. 
Results: In the 100 days prior to recruitment, 83.1% of the participants received at least one 
anticholinergic or sedative medication included in the DBI and 82.7% received at least one 
PIM according to the Beers Criteria. Multi-level linear models showed there was a significant 
association between higher DBI and lower quality of life according to the EQ-5D-5L (β (SE): 
-0.034 (0.012), p=0.006) after adjustment for potential confounding factors. Increasing 
numbers of PIMs were also associated with lower EQ-5D-5L scores (-0.030 (0.010), 
p=0.003) and DEMQOL-Self-Report-Utility scores (-0.020 (0.009), p=0.029). Exposure to 
both DBI-associated medications and PIMs was associated with lower DEMQOL-Self-
Report-Utility scores (-0.034 (0.017), p=0.049). 
Conclusion: Exposure to anticholinergic and sedative medications and PIMs occurred in over 
three-quarters of a population of older adults in residential care and was associated with a 






 Potentially inappropriate medications, according to the Beers Criteria, and 
anticholinergic and sedative medications, described in the Drug Burden Index, were 
highly prevalent in residential aged care (82.7% and 73.0%). 
 Higher exposure to anticholinergic and sedative medications and higher exposure to 
potentially inappropriate medications were associated with lower quality of life in 
residents of aged care. 
 This study provides evidence to support that there is a need for greater adherence to 
recommendations for appropriate medication use in residential aged care. 
1 Introduction 
It is important to explore factors which influence quality of life in older adults living in long-
term residential care in order to identify intervention strategies to improve their quality of 
life. A lower quality of life is associated with a decline in activities of daily living and also 
mortality in this population [1]. Polypharmacy may negatively impact the quality of life of 
individuals living in aged care facilities, but it remains unclear which medications may lead 
to this reduction in quality of life [2]. Medications should be appropriately prescribed for the 
individual where the benefits of the medication outweigh its potential harms. 
Quality of life for older adults living in residential care has been described as the “degree to 
which an individual resident’s overall well-being meets their personal expectations, the 
expectations of their carers or the expectations of the community” [3]. Many factors can 
impact the quality of life of older adults such as health status (including co-morbidities), 
social engagement, cognitive function and medication use [4]. However, these associations 
are less clear in people living in residential aged care facilities and those living with dementia 





dementia [6], it is difficult for policy-makers to determine where to focus efforts to improve 
quality of life for the residents.  
Potentially inappropriate medications (PIMs) are often identified using validated measures 
such as the Beers Criteria for older adults [7]. Previously, the Beers Criteria have been shown 
to be associated with an increased risk of hospitalization and mortality in older adults living 
in residential care [8]. The criteria were updated in 2015 by the American Geriatrics Society 
and the statement includes lists of PIMs which are strongly recommended to be avoided in all 
older adults and additional medications which should be avoided in those with cognitive 
impairment and dementia. PIMs according to the Beers Criteria have been shown to be 
commonly used in older adults in residential care settings, but other measures of drug burden 
may be more useful in this population for predicting certain clinical outcomes [9].  
The Drug Burden Index (DBI) is a measure to determine exposure to anticholinergic and 
sedative medications [10-12]. The DBI has been associated with falls and worse functional 
outcomes in older adults in residential facilities; however, associations with mortality in 
different populations and settings remain unclear [9, 13-15]. The DBI may be more strongly 
associated with functional impairment than the Beers Criteria in an Australian retirement 
village setting [9], but further exploration of the DBI compared to the Beers Criteria in 
different populations is needed.  
Determining if the DBI or PIMs are associated with quality of life for individuals living in 
residential aged care is important in order to develop targeted intervention strategies to 
improve quality of life for these individuals. The main objective of this study was to examine 
whether the DBI and PIMs according to the Beers Criteria were associated with quality of life 
in older adults living in residential care facilities with a high prevalence of cognitive 






2.1 Study participants 
The participants were those included in the Investigating Services Provided in the Residential 
Environment for Dementia (INSPIRED) study, a cross-sectional study of residential aged 
care facilities in Australia. In Australia, when a person applies for aged care they complete an 
aged care assessment to determine what level of care they require. Residential care services 
provide accommodation and support for people who can no longer live at home. Some 
individuals may be referred to an aged care facility specific to their needs (such as dementia-
specific facilities), however, admission to residential aged care facilities is often based on 
availability at the time of need. 
The INSPIRED study was specifically designed to allow the inclusion of those living with 
cognitive impairment and dementia. The INSPIRED study received ethical approval from the 
Flinders Social and Behavioural Research Ethics Committee. The study aimed to include 
facilities from areas representing different socioeconomic backgrounds, geographic locations 
(e.g. rural vs metropolitan locations) and different states of Australia. In total, 17 facilities, 
from 5 different not-for profit organisations, in South Australia, New South Wales, Western 
Australia and Queensland participated in the study. Consent for the participants to be 
involved in the study was either by self-consent or, when the participant had severe cognitive 
impairment, informed consent and data collection was undertaken with a proxy, i.e. usually a 
close family member (76% of the participants). Participants were able to take part if they (a) 
had been a permanent resident in the facility for 12 months or more, (b) were not in 
immediate palliative care, (c) had no complex medical or family issues which would impede 
their participation and (d) had a family member available and willing to participate on behalf 





A total of 1323 residents of the participating facilities were assessed for eligibility; 901 were 
eligible to participate and 60% of these (n=541) consented to be part of the study. Data 
collection was completed between January 2015 and February 2016.  
2.2 Determination of medication use of the participants 
Medication use was primarily based on dispensing records obtained from the appropriate 
pharmacy. The data collected included the name, dose, dosing instructions and dispensed 
dates of all the medications dispensed 100 days prior to the start date of the study at each 
facility. Of the study participants, 3.5% (n=19) did not have available pharmacy records and 
reviews of their medication charts were undertaken instead. Exposure to a PIM or DBI 
medication was defined as exposure to an affected medication during the 100 days.  
2.3 Drug Burden Index and potentially inappropriate medications by the Beers Criteria 
DBI exposure for all resident records was calculated as the sum of exposure to each 





where D represents the daily dose taken by the subject and ∂ the minimum recommended 
daily dose registered by the Therapeutic Goods Administration of Australia, as an estimate of 
the DR50 (dose required for 50% of the maximal therapeutic effect). The Australian product 
information was used to identify medications with clinically significant anticholinergic and/or 
sedative effects. Complementary medications and medications prescribed as “when required” 
were excluded from DBI calculations.   
The average daily dose was calculated using the following equation: 
D = 







where Q represents the quantity dispensed, d represents the daily dose dispensed, and I the 
number of times the medication was dispensed over the 100 days. If dosing instructions were 
missing or incomplete, the initial starting dose according to the Australian Product 
Information was used.  
PIMs were identified using the 2015 updated Beers Criteria for all older adults, independent 
of diagnosis. We also completed a subgroup analysis to examine the separate Beers Criteria 
list specific for people with cognitive impairment and dementia in addition to the Beers 
Criteria for all older adults. The Beers Criteria were developed in an American setting and 
therefore some medications were added to the PIMs lists by research pharmacists to allow for 
the Australian Register of Therapeutic Goods; these medications were in the same classes as 
medications that were included in the Beers Criteria lists (Electronic Supplementary Material 
Table S1).  
2.4 Quality of life measures  
In the INSPIRED study, quality of life was measured after participant enrolment into the 
study at the time of data collection. The quality of life of the participants was determined 
using three different measurement tools (a) a measure of generic health-related quality of life: 
the EuroQol five dimensions questionnaire (EQ-5D-5L, self-completed or completed by a 
proxy) [16], (b) the DEMQOL a dementia specific measure of health-related quality of life 
assessment (self-reported) and (c) the DEMQOL-Proxy (completed by a proxy on behalf of 
the participant). The EQ-5D-5L covers five dimensions influencing health-related quality of 
life: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-
5D-5L has a maximum score of 1 with higher scores indicating a better quality of life. 
DEMQOL-Utility scores are based on five different dimensions (positive emotion, negative 





based on four dimensions (positive emotion, negative emotion, memory and appearance). The 
range for the DEMQOL-Utility scores is from 0.243 to 0.986 and for the DEMQOL-Proxy-
Utility scores is from 0.363 to 0.937; higher scores indicating a better quality of life. Utility 
scores were determined from the DEMQOL, DEMQOL-Proxy and EQ-5D-5L assessments 
by applying preference-weights based on the preferences of members of the UK general 
population [17, 18].  
2.5 Covariates 
The INSPIRED dataset included participant-level characteristic measures for cognitive 
function (the Psychogeriatric Assessment Scales-Cognitive Impairment Scale (PAS-Cog) 
score; higher scores indicate worse cognitive function), activities of daily living (the Barthel 
Index) and behaviour (the Neuropsychiatric Inventory, NPI). Social interaction was based on 
self-report of whether the participant had interaction with close social ties (relatives and 
friends) at least once per week. Medical histories from the facilities were used to determine if 
the participants had a clinical diagnosis of dementia. Comorbidities were extracted from the 
medical records of the participants and grouped into one of ten disease categories (excluding 
dementia) as used by Cohen-Mansfield and colleagues [19]. Facility-level characteristics 
were determined from information collected in a standardised questionnaire which has been 
validated in an older residential care population [20]. This included 33 questions and the 
facility-level covariates used in this study were location, number of direct care hours per 
resident and size of facility. The age, sex and marital status of the participant were also 
considered as covariates in this study.  
2.6 Statistical analysis 
Multi-level linear models were used to examine associations between (a) DBI (continuous 





different PIMs (continuous variable) or (d) having a DBI>0 and exposure to a PIM and 
quality of life measures. As the participants were clustered in 17 different residential aged 
care facilities, the data had a two-level hierarchal structure; therefore, two-level multi-level 
models with random intercepts and independent variance components were used to perform 
the data analyses. The models were adjusted for both the participant-level characteristics and 
facility-level characteristics as described in Section 2.5. Adjustments for education level were 
not undertaken due to a high level of missing data (26.2%). The level of statistical 
significance was set at p<0.05. All analyses were completed using Stata v.14.0 (Stata Corp 
LP, College Station, TX, USA). 
3 Results 
3.1 Characteristics of the participants 
Of the total participants of the INSPIRED study, 82.8% (n=448) had mild to severe levels of 
cognitive impairment based on their PAS-Cog score and 64.3% (n=348) had received a 
clinical diagnosis of dementia. The mean age of the participants was 85.5 (±SD 8.5) years old 
and 74.5% (n=403) were female. The participants had a mean number of 3.7 (±1.4) co-
morbid conditions. The median (IQR) total number of different medications a participant was 
exposed to was 10 (7-13); 38.2% of participants were exposed to 5-9 medications and 52.3% 
of participants were exposed to ≥10 medications. Further characteristics are shown in Table 
1.  
3.2 Drug Burden Index and Beers Criteria for the total study population 
No medication data were available for four of the participants, therefore, the effective sample 
analysed was 537 participants (99.3%) (Figure 1). Of the 537 participants, 83.1% (n=446) 
had been exposed to at least one medication which contributed to their DBI, therefore the 





DBI for all participants was 0.86 (0.36-1.52). According to the Beers Criteria for all older 
adults, 73.0% (n=392) of the participants had been exposed to a PIM (number of PIMs 
ranged from 0 to 6). Those exposed to a PIM were more likely to also be exposed to a DBI-
associated medication (p<0.001). Of the 392 participants exposed to a PIM according to the 
Beers Criteria, 89.3% (n=350) were also exposed to a DBI-associated medication. Of the 145 
participants not exposed to a PIM, 33.8% (n=49) were also not exposed to a DBI-associated 
medication.  
The most common PIMs according to the Beers Criteria for all older adults were proton-
pump inhibitors for more than 8 weeks (41.5%), benzodiazepines (30.5%) and antipsychotics 
(24.8%). The prevalence of the remaining PIMs was relatively small (all <10%). The most 
prevalent medication classes contributing to the DBI were antidepressants (mirtazapine, 
17.1%, sertraline, 9.5%, escitalopram, 8.6% and citalopram, 7.1%) and opioid analgesics 
(buprenorphine, 14.3%, fentanyl, 9.7% and oxycodone, 8.2%). The most frequently identified 
benzodiazepine was temazepam (9.9%) and the most common antipsychotic was risperidone 
(12.7%).  
3.3 Drug Burden Index, potentially inappropriate medications and quality of life 
Table 2 shows the associations of the DBI and PIMs according to the Beers Criteria for all 
older adults with the different quality of life outcomes included in the INSPIRED study. 
Adjusted linear mixed models showed that higher DBI scores were associated with lower 
EQ-5D-5L utility scores, but not DEMQOL-Proxy-Utility or DEMQOL-Self-Report-Utility 
scores. For every unit increase in DBI, the EQ-5D-5L utility scores decreased by 0.034 
(p=0.006).  
Being exposed to at least one PIM according to the Beers Criteria for all older adults was not 





exposed to a PIM. However, when analysing the number of PIMs a person was exposed to, 
for every additional PIM a participant was exposed to the DEMQOL-Self-Report-Utility 
scores decreased by 0.020 (p=0.029) and the EQ-5D-5L decreased by 0.030 (p=0.003). 
Having a DBI>0 and being exposed to at least one PIM was associated with a decrease in 
DEMQOL-Self-Report-Utility scores by 0.034 (p=0.049). 
3.4 Potentially inappropriate medications for dementia and cognitive impairment and 
quality of life: subgroup analysis  
Of the participants, 86.5% (n=465) had a diagnosis of dementia or cognitive impairment 
according to their PAS-Cog score (PAS-Cog ≥4) and were included in this subgroup analysis. 
Of those with cognitive impairment or a diagnosis of dementia, 72.5% (n=337) were 
identified as being exposed to a PIM that is not recommended for older adults and/or 
contraindicated in dementia or cognitive impairment. Similar to the results for PIMs for all 
participants, exposure to a PIM (yes vs. no) was not associated with any quality of life 
measures after adjusting for confounding factors (Table 3). An increasing number of PIMs 
was associated with two of the measures of quality of life in this subgroup. For every 
additional PIM a participant was exposed to the DEMQOL-Self-Report-Utility scores 
decreased by 0.024 (p=0.003) and the EQ-5D-5L utility scores decreased by 0.027 (p=0.004). 
4 Discussion 
In this study, higher exposure to anticholinergic and sedative medications as identified in the 
DBI and higher exposure to PIMs according to the Beers Criteria were both associated with 
lower quality of life in a population of older adults with a high prevalence of cognitive 
impairment and dementia. Increasing numbers of PIMs according to the Beers Criteria were 
associated with both lower EQ-5D-5L and DEMQOL utility scores after adjusting for a wide-





5L utility scores only. Both DBI-associated medications and PIMs according to the Beers 
criteria were highly prevalent in this population (>80%).  
There is external validity in the association between DBI and the EQ-5D-5L, but not the 
DEMQOL. The DBI was developed to measure the functional burden of medications [10, 11] 
and the EQ-5D-5L captures physical function (mobility, self-care and usual activities) while 
the DEMQOL does not. A previous cross-sectional study also found an association between 
DBI and lower health-related quality of life in older adults with dementia living in residential 
settings, but did not find an association with PIMs according to the Beers Criteria [21]. This 
result is consistent with the current findings as in this analysis we also found no significant 
association of exposure to PIMs according to the Beers Criteria (when analysed as a 
dichotomous measure) with quality of life. However, we extended this analysis by also 
examining the degree of exposure to PIMs according to the Beers Criteria, considering it as a 
continuous measure, and this was associated with lower quality of life in this population. Due 
to the high prevalence of PIMs in this population, it is considered appropriate to consider the 
extent of PIMs use and to conduct the analysis as a continuous measure in this setting.  
The associations between DBI and number of PIMs according to the Beers Criteria and lower 
quality of life, although statistically significant, all had a relatively small effect on the 
different utility scores. The largest difference seen was a 1-unit increase in the DBI (e.g. 
exposure to two drugs with anticholinergic or sedative effects at their minimum efficacious 
doses) resulting in a decrease of 0.034 according to the EQ-5D-5L. Similarly, being exposed 
to a DBI medication and a PIM was associated with a decrease of 0.034 DEMQOL-Self-
Report-Utility score compared to not being exposed to a DBI medication or PIM. The precise 
clinically meaningful difference in the quality of life scores used in this study population 
remains unclear, but previous literature has suggested a clinically meaningful difference in 





studied [22-24]. This would suggest that many of the associations seen in this study between 
the number of PIMs a participant was exposed to and quality of life utility measures may not 
be clinically meaningful (between 0.020 and 0.030 difference in quality of life with exposure 
to an additional PIM); however, the cumulative impact of multiple PIMs may be clinically 
significant. Studies powered to detect a smaller change in quality of life measures may be 
able to detect differences, or it may be useful to explore associations between other criteria 
for inappropriate medications and quality of life in older populations living in residential 
aged care if further information is collected regarding their indication and medical conditions, 
such as the Basger’s criteria [25]. 
Polypharmacy (5-9 medications) and hyperpolypharmacy (≥10 medications) were highly 
prevalent in this population. Deprescribing has been suggested as a potential method to 
reduce inappropriate polypharmacy in residential aged care settings. Deprescribing involves a 
completion of a review of an individual’s current medications and subsequent withdrawal of 
inappropriate medications with supervision from a healthcare professional after careful 
consideration of the likelihood of adverse events with a goal of improving clinical outcomes 
[26, 27]. Interventions for deprescribing have been trialled in residential aged care facilities, 
however the effects of these interventions as shown in randomised controlled trials (RCTs) 
have been mixed and further studies are required [28-33, 26]. The high prevalence of DBI-
associated medications and PIMs according to the Beers Criteria in the current study suggests 
that current recommendations for appropriate medication use in older adults may need to be 
better implemented in residential aged care settings. Further studies could examine if 
deprescribing of medications included in the DBI or Beers Criteria may improve quality of 
life outcomes for these individuals as well as improve other outcomes associated with 






The INSPIRED study is a large study in this setting and this study was designed to allow the 
inclusion of individuals with cognitive impairment and dementia. Further, a thorough 
examination of quality of life in this population was completed which is uncommon in this 
population. Although the cross-sectional nature of the data in the study could leave the 
findings open to the effects of confounding, we were able to reduce this risk by adjusting for 
a wide-range of potential confounding factors due to the comprehensive data collected in this 
study. Although it is more usual to examine medication use from medication charts, the 
majority of the dispensing data used were collected from electronic records held by the 
individual pharmacies associated with the residential aged care facilities. This approach has 
some advantages as these records are inclusive of all of the medications dispensed to the 
individuals whilst at the facility. A particular strength of the study is that we were able to 
compare two established measures for identifying potentially inappropriate medications in 
this study. Furthermore, within this population, as only a minority of participants did not 
receive PIMs and a large number of different PIMs were prescribed, examining the number 
of PIMs prescribed was also feasible. An inherent limitation of the cross-sectional design of 
the study is the inability to assess causality or the direction of any observed association. It is 
possible that the lower quality of life with increasing exposure to PIMs or DBI-associated 
medications seen in this study may be leading to exposure to the medications rather than the 
medications causing the lower quality of life. As a high proportion of people in the study 
were not able to self-complete assessments, proxy measures were used and, although this 
meant that these people could be included in the study, there may be differences between 
what the proxy reports and what the individual would report if they were able. Even so, the 
EQ-5D-5L by proxy has been previously validated in residents living in aged care facilities 






In this population of older adults living in residential aged care facilities with a high 
prevalence of cognitive impairment and dementia, exposures to anticholinergic and sedative 
medications, as measured with the DBI, and exposure to PIMs, according to the Beers 
Criteria, were highly prevalent. Exposure to increasing DBI and increasing numbers of PIMs, 
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Table 1. Characteristics of the participants of the INSPIRED Study (n=541). 
Characteristic Value 
Age (y), mean (SD) 85.5 (8.5) 
Female, n (%) 403 (74.5) 
Married, n (%) 137 (25.3) 
Barthel Index, median (IQR) 35 (9-71) 
DEMQOL proxy, median (IQR) 0.67 (0.60-0.82) 
DEMQOL resident, median (IQR) 0.88 (0.79-0.94) 
EQ-5D-5L resident or proxy, median (IQR) 0.54 (0.28-0.78) 
NPI, median (IQR) 7 (3-12) 
PAS-Cog, median (IQR) 15 (6-21) 
Dementia diagnosis, n (%) 348 (64.3) 
Number of co-morbid conditions, mean (SD) 3.7 (1.4) 
Total number of medications, median (IQR) 10 (7-13) 
DBI>0, n (%) 446 (82.4) 
DBI, median (IQR) 0.86 (0.36-1.52) 
Exposed to a PIM, n (%) 392 (73.0) 
Total number of PIMs, median (IQR) 1 (0-2) 




Table 2. Associations between the Drug Burden Index and potentially inappropriate 
medications as listed by the Beers Criteria for all older adults and quality of life of the 
participants. 
Quality of life 
measures 
DBI,  
β (SE), P value 
PIM,  
β (SE), P value 
Increasing number 
of PIMs,  
β (SE), P value 
DBI and PIMs, 
β (SE), P value 
Unadjusted models  
DEMQOL-Proxy-
Utility scores  
-0.001 (0.006), 0.841 -0.010 (0.013), 0.436 -0.007 (0.005), 0.207 -0.016 (0.012), 0.189 
DEMQOL-Self-
Report-Utility scoresa 
-0.015 (0.009), 0.093 -0.016 (0.023), 0.500 -0.017 (0.007), 0.046 -0.038 (0.017), 0.028 
EQ-5D-5L scores (self-
report or proxy)  
-0.048 (0.014), 0.001 -0.021 (0.030), 0.491 -0.031 (0.011), 0.009 -0.057 (0.027), 0.03 
Adjusted modelsb  
DEMQOL-Proxy-
Utility scores  
-0.006 (0.007), 0.397 -0.016 (0.014), 0.246 -0.009 (0.005), 0.116 -0.022 (0.012), 0.07 
DEMQOL-Self-
Report-Utility scoresa 
-0.012 (0.009), 0.181 -0.015 (0.023), 0.510 -0.020 (0.009), 0.029 -0.034 (0.017), 0.049 
EQ-5D-5L scores (self-
report or proxy)  




Abbreviations: DBI, Drug Burden Index; DEMQOL, Dementia quality of life questionnaire; EQ-5D-5L, EuroQol 
five dimensions questionnaire; PIM, potentially inappropriate medication. aOnly includes those who could self-
consent (n=228). bThe models are adjusted for resident-level characteristics (age, sex, marital status, PAS-Cog 
scores, Neuropsychiatric Inventory, dementia diagnosis, number of co-morbid conditions, social ties and Barthel 
Index) and facility-level characteristics (size of residential facility, number of direct care hours and location). 
Abbreviations: DBI, Drug Burden Index; DEMQOL, Dementia quality of life questionnaire; EQ-5D-
5L, EuroQol 5 Dimensions 5 Levels; IQR, Inter-quartile range; NPI, Neuropsychiatric Inventory; PAS-
Cog, Psychogeriatric Assessment Scales-Cognitive Impairment Scale; PIM, potentially inappropriate 
medication. 
 





Table 3. Associations between potentially inappropriate medications as listed by the Beers 
Criteria for people with cognitive and dementia and quality of life of participants with 
cognitive impairment and dementia. 
Quality of life measures PIM for cognitive 
impairment and 
dementia,  
β (SE), P value 
Increasing number of 
PIMs for cognitive 
impairment and 
dementia,  
β (SE), P value 
Unadjusted models   
DEMQOL-Proxy-Utility scores  -0.017 (0.014), 0.204 -0.006 (0.005), 0.200 
DEMQOL-Self-Report-Utility 
scoresa 
-0.031 (0.024), 0.201 -0.019 (0.008), 0.022 
EQ-5D-5L scores (self-report or 
proxy)  
-0.017 (0.031), 0.573 -0.026 (0.011), 0.022 
Adjusted modelsb   
DEMQOL-Proxy-Utility scores  -0.021 (0.014), 0.130 -0.007 (0.005), 0.142 
DEMQOL-Self-Report-Utility 
scoresa 
-0.034 (0.023), 0.145 -0.024 (0.008), 0.003 
EQ-5D-5L scores (self-report or 
proxy)  




PIMs included the PIMs for all older adults and the additional PIMs for adults with cognitive impairment and 
dementia. Abbreviations: DEMQOL, Dementia quality of life questionnaire; EQ-5D-5L, EuroQol five dimensions 
questionnaire; PIM, potentially inappropriate medication. aOnly includes those who could self-consent (n=160).  
bThe models are adjusted for resident-level characteristics (age, sex, marital status, PAS-Cog scores, 
Neuropsychiatric Inventory, dementia diagnosis, number of co-morbid conditions, social ties and Barthel Index) and 





Electronic Supplementary Material Table S1. Complete list of medications considered 
potentially inappropriate, according to the Beers Criteria, and adapted for an Australian 
setting. 
PIMs for all older adults Additional PIMs for adults with cognitive 
impairment or dementia 










Antiparkinsonian agents Pheniramine 
Benzatropine* Trimeprazine 
Biperiden  
Trihexyphenidyl Antimuscarinics (urinary incontinence)  
 Darifenacin 
Antispasmodics Fesoterodine 
Atropine (excludes ophthalmic) Flavoxate 












Peripheral alpha-1 blockers H2-receptor antagonists 
Prazosin* Cimetidine 
Terazosin Famotidine 
 Nizatidine*  
Central alpha blockers Ranitidine* 
Clonidine  




Other cardiovascular medications  
Amiodarone*   
Digoxin*  
Nifedipine, immediate release*  
  
Antidepressants, alone or in combination  
Amitriptyline*  
Clomipramine  






















































Estrogens with or without progestins (not vaginal 
creams) 

























































Medications were added to the list including medications that are in the same classes as medications that were 
listed in the Beers Criteria and are available in Australia. Medications that are no longer available in Australia 
are not listed here. 
*Dispensed to participants of the INSPIRED study. 
 
